Tumour sphere assays on BRCA CSCs indicated that GCN5 inhibition with GS4027 and L-Moses reduces CSC self-renewal (Supplementary Fig. 10h) and β-catenin-dependent promoter activation (Supplementary Fig. 10i), similar to PDAC CSCs. Here, KAT2A is linked to neoplasm.